xl281
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00451880)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
BRAF inhibitor
Selectively targets RAF kinases including BRAF, RAF1 and the BRAF mutant (V600E) (http://www.exelixis.com/sites/default/files/pdf/XL281-001_ASCO-2009.pdf)
- Serine/threonine-protein kinase RAFINHIBITOR
RAF1 inhibitor
Selectively targets RAF kinases including BRAF, RAF1 and the BRAF mutant (V600E) (http://www.exelixis.com/sites/default/files/pdf/XL281-001_ASCO-2009.pdf)
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1- Mol. weight
- 462.89 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545027 ↗
Also known as
- bms-908662
- bms-908662
- bms-908662
- bms-908662
- exel-2819
- exel-2819
- xl281
- xl281
- xl281
- xl-281
- xl-281
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01245556 | Phase 1 | Jan 1, 2011 | Bristol-Myers Squibb |
| NCT01086267 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2010 | Bristol-Myers Squibb |
| NCT00451880 | Phase 1 | Feb 1, 2007 | Exelixis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 2 | 2 | 2 | 2010 |
| Exelixis | For profit | 1 | 1 | 1 | 2007 |
2 organizations
Page 1 / 1